227 related articles for article (PubMed ID: 30742565)
1. Ovarian Suppression in Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
Pan K; Bosserman LD; Chlebowski RT
J Clin Oncol; 2019 Apr; 37(11):858-861. PubMed ID: 30742565
[No Abstract] [Full Text] [Related]
2. Adjuvant endocrine therapy for premenopausal women: risk stratification, type and duration.
Francis PA
Breast; 2019 Nov; 48 Suppl 1():S85-S88. PubMed ID: 31839169
[TBL] [Abstract][Full Text] [Related]
3. Ovarian suppression for early breast cancer.
Wilcken N; Stockler M
Lancet; 2007 May; 369(9574):1668-70. PubMed ID: 17512837
[No Abstract] [Full Text] [Related]
4. Which is the appropriate adjuvant endocrine therapy for premenopausal patients with breast cancer?
Petrelli F; Barni S
Clin Breast Cancer; 2015 Jun; 15(3):169-70. PubMed ID: 25600162
[No Abstract] [Full Text] [Related]
5. Aromatase inhibitor plus ovarian suppression as adjuvant therapy in premenopausal women with breast cancer.
Figg WD; Cook K; Clarke R
Cancer Biol Ther; 2014; 15(12):1586-7. PubMed ID: 25535893
[TBL] [Abstract][Full Text] [Related]
6. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
Francis PA; Pagani O; Fleming GF; Walley BA; Colleoni M; Láng I; Gómez HL; Tondini C; Ciruelos E; Burstein HJ; Bonnefoi HR; Bellet M; Martino S; Geyer CE; Goetz MP; Stearns V; Pinotti G; Puglisi F; Spazzapan S; Climent MA; Pavesi L; Ruhstaller T; Davidson NE; Coleman R; Debled M; Buchholz S; Ingle JN; Winer EP; Maibach R; Rabaglio-Poretti M; Ruepp B; Di Leo A; Coates AS; Gelber RD; Goldhirsch A; Regan MM;
N Engl J Med; 2018 Jul; 379(2):122-137. PubMed ID: 29863451
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer.
Mathew A; Davidson NE
Breast; 2015 Nov; 24 Suppl 2():S120-5. PubMed ID: 26255743
[TBL] [Abstract][Full Text] [Related]
8. Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer.
Conte B; Poggio F; Del Mastro L
Expert Opin Pharmacother; 2017 Sep; 18(13):1357-1362. PubMed ID: 28764603
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant ovarian suppression in premenopausal breast cancer.
Francis PA; Regan MM; Fleming GF; Láng I; Ciruelos E; Bellet M; Bonnefoi HR; Climent MA; Da Prada GA; Burstein HJ; Martino S; Davidson NE; Geyer CE; Walley BA; Coleman R; Kerbrat P; Buchholz S; Ingle JN; Winer EP; Rabaglio-Poretti M; Maibach R; Ruepp B; Giobbie-Hurder A; Price KN; Colleoni M; Viale G; Coates AS; Goldhirsch A; Gelber RD; ;
N Engl J Med; 2015 Jan; 372(5):436-46. PubMed ID: 25495490
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant endocrine therapy for premenopausal women with early breast cancer.
Bao T; Davidson NE
Breast Cancer Res; 2007; 9(6):115. PubMed ID: 18190722
[TBL] [Abstract][Full Text] [Related]
11. Predicting benefit of endocrine therapy for early breast cancer.
Regan MM
Breast; 2015 Nov; 24 Suppl 2(0 2):S129-31. PubMed ID: 26255197
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials.
Regan MM; Pagani O; Fleming GF; Walley BA; Price KN; Rabaglio M; Maibach R; Ruepp B; Coates AS; Goldhirsch A; Colleoni M; Gelber RD; Francis PA; ;
Breast; 2013 Dec; 22(6):1094-100. PubMed ID: 24095609
[TBL] [Abstract][Full Text] [Related]
13. Controversies in adjuvant endocrine treatment of premenopausal women.
Goldstein LJ
Clin Breast Cancer; 2006 Feb; 6 Suppl 2():S36-40. PubMed ID: 16595024
[TBL] [Abstract][Full Text] [Related]
14. Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Gnant M; Mlineritsch B; Schippinger W; Luschin-Ebengreuth G; Pöstlberger S; Menzel C; Jakesz R; Seifert M; Hubalek M; Bjelic-Radisic V; Samonigg H; Tausch C; Eidtmann H; Steger G; Kwasny W; Dubsky P; Fridrik M; Fitzal F; Stierer M; Rücklinger E; Greil R; ; Marth C
N Engl J Med; 2009 Feb; 360(7):679-91. PubMed ID: 19213681
[TBL] [Abstract][Full Text] [Related]
15. The aromatase inhibitors (plus ovarian function suppression) in premenopausal breast cancer patients: ready for prime time?
Montagna E; Cancello G; Colleoni M
Cancer Treat Rev; 2013 Dec; 39(8):886-90. PubMed ID: 23725877
[TBL] [Abstract][Full Text] [Related]
16. Aromatase inhibitors in adjuvant therapy of breast cancer: before, instead of, or beyond tamoxifen.
Pritchard KI
J Clin Oncol; 2005 Aug; 23(22):4850-2. PubMed ID: 16009956
[No Abstract] [Full Text] [Related]
17. Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM).
Gori S; Puglisi F; Cinquini M; Pappagallo G; Frassoldati A; Biganzoli L; Cortesi L; Fiorentino A; Angiolini C; Tinterri C; De Censi A; Levaggi A; Del Mastro L
Eur J Cancer; 2018 Aug; 99():9-19. PubMed ID: 29886394
[TBL] [Abstract][Full Text] [Related]
18. Endocrinology and hormone therapy in breast cancer: endocrine therapy in premenopausal women.
Pritchard K
Breast Cancer Res; 2005; 7(2):70-6. PubMed ID: 15743514
[TBL] [Abstract][Full Text] [Related]
19. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Sharma R; Hamilton A; Beith J
Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant endocrine therapy for breast cancer.
Rao RD; Cobleigh MA
Oncology (Williston Park); 2012 Jun; 26(6):541-7, 550, 552 passim. PubMed ID: 22870539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
